Jamison Private Wealth Management Inc. Has $1.82 Million Stock Holdings in Abbott Laboratories (NYSE:ABT)

Jamison Private Wealth Management Inc. lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 27.0% in the fourth quarter, HoldingsChannel reports. The fund owned 16,084 shares of the healthcare product maker’s stock after buying an additional 3,420 shares during the period. Jamison Private Wealth Management Inc.’s holdings in Abbott Laboratories were worth $1,819,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Bath Savings Trust Co lifted its position in Abbott Laboratories by 3.7% during the 4th quarter. Bath Savings Trust Co now owns 166,132 shares of the healthcare product maker’s stock valued at $18,791,000 after purchasing an additional 5,881 shares during the period. Simplify Asset Management Inc. raised its position in shares of Abbott Laboratories by 67.3% in the 3rd quarter. Simplify Asset Management Inc. now owns 14,083 shares of the healthcare product maker’s stock valued at $1,606,000 after acquiring an additional 5,664 shares during the period. Pensionfund Sabic bought a new position in Abbott Laboratories during the 4th quarter worth approximately $2,828,000. Sequoia Financial Advisors LLC increased its stake in Abbott Laboratories by 19.6% in the third quarter. Sequoia Financial Advisors LLC now owns 193,764 shares of the healthcare product maker’s stock valued at $22,091,000 after purchasing an additional 31,720 shares in the last quarter. Finally, Tidal Investments LLC raised its holdings in Abbott Laboratories by 30.5% in the third quarter. Tidal Investments LLC now owns 107,308 shares of the healthcare product maker’s stock worth $12,234,000 after purchasing an additional 25,052 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $125.12 on Friday. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The company has a market cap of $217.01 billion, a PE ratio of 16.36, a price-to-earnings-growth ratio of 2.51 and a beta of 0.73. The company has a 50 day moving average of $115.26 and a 200-day moving average of $113.31. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $125.67.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $11,029,400 billion. During the same quarter in the previous year, the business posted $1.19 earnings per share. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. As a group, equities research analysts forecast that Abbott Laboratories will post 5.15 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.89%. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. Abbott Laboratories’s payout ratio is currently 30.85%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ABT. Mizuho upped their price objective on shares of Abbott Laboratories from $115.00 to $130.00 and gave the company a “neutral” rating in a research report on Thursday, October 17th. Oppenheimer assumed coverage on Abbott Laboratories in a research report on Tuesday, October 8th. They set an “outperform” rating and a $130.00 price target on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $135.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, January 21st. UBS Group raised their target price on shares of Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Morgan Stanley increased their price objective on shares of Abbott Laboratories from $107.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.50.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.